title: Radiation recall dermatitis induced by pazopanib.
abstract: BACKGROUND
  Pazopanib is a multi-targeted tyrosine kinase inhibitor that has recently been approved for treatment of advanced clear cell renal cell carcinoma (RCC). There are no previous reports of pazopanib triggering radiation recall dermatitis (RRD).
  
  
  METHODS
  A 60-year-old male patient was commenced on pazopanib for metastatic RCC 2 weeks prior to receiving radiotherapy (10×30 Gy) to bone metastases at the T9 and L4 vertebrae and right mid-shaft of humerus. Although there were no immediate complications from radiotherapy, 2 weeks after finishing radiation he developed a pruritic, erythematous, maculo-papular rash localized to the T9 and right humeral radiotherapy fields. The patient was diagnosed with RRD induced by pazopanib and commenced on a course of oral prednisolone, which resulted in resolution of his rash. He has now completed 5 months of pazopanib with no recurrence of RRD.
  
  
  CONCLUSIONS
  We report the first case of RRD triggered by pazopanib. With increasing use of pazopanib for advanced RCC, clinicians must be aware of the possibility that RRD can occur in patients treated with this agent following radiotherapy.
authors.affiliation: Joint Austin-Ludwig Oncology Unit, Austin Health, Melbourne, Australia.
authors.forename: Arun
authors.initials: A
authors.lastname: Azad
authors.forename: Claire
authors.initials: C
authors.lastname: Maddison
authors.forename: Josephine
authors.initials: J
authors.lastname: Stewart
mesh_terms: D002292:Carcinoma, Renal Cell / Q000150:complications / Q000628:therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects*; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D007191:Indazoles; D007680:Kidney Neoplasms / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D011855:Radiodermatitis / Q000209:etiology* / Q000517:prevention & control; D020266:Radiotherapy, Conformal / Q000009:adverse effects*; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib